METHODS: The relevant databases were searched to collect the clinical trials on brachytherapy in patients with CPs. Included studies were limited to publications in full manuscript form with at least 5-year median follow-up, and adequate reporting of treatment outcomes and adverse reactions data. Stata 12.0 was used for data analysis.
RESULTS: According to the inclusion and exclusion criteria, a total of 6 clinical trials involving 266 patients with CPs were included in this meta-analysis. The minimum average follow-up was 5 years. The results of the meta-analysis showed that 1-year, 2-3 years and 5 years progression free survival rates (PFS) are 75% (95%CI: 66-84%), 62% (95%CI: 52-72%) and 57% (95%CI: 22-92%), respectively. At the last follow-up, less than 16% of patients with visual outcomes worser than baseline in all included studies. While, for endocrine outcomes, less than 32% of patients worser than baseline level.
CONCLUSIONS: In general, based on the above results, brachytherapy should be considered as a good choice for the treatment of CP.
方法:检索相关数据库以收集CPs患者近距离放射治疗的临床试验。纳入的研究仅限于完整手稿形式的出版物,至少有5年的中位随访时间。并充分报告治疗结果和不良反应数据。Stata12.0用于数据分析。
结果:根据纳入和排除标准,本荟萃分析共纳入6项临床试验,涉及266例CPs患者.最低平均随访时间为5年。荟萃分析的结果表明,1年,2-3年和5年无进展生存率(PFS)为75%(95CI:66-84%),62%(95CI:52-72%)和57%(95CI:22-92%),分别。在最后一次随访中,在所有纳入研究中,视力结局比基线差的患者中,少于16%.同时,对于内分泌结果,少于32%的患者比基线水平恶化。
结论:一般来说,基于上述结果,近距离放射治疗应被视为治疗CP的良好选择.